You are here: Home » PTI Stories » National » News
Business Standard

Laurus Labs gets USFDA nod for diabetes drug

Press Trust of India  |  New Delhi 

Drug firm today said it has received approval from the US health regulator for its hydrochloride tablets used for treatment of

The company has received approval from Food and Drug Administration (USFDA) for hydrochloride tablets USP in the strengths of 500 mg, 850 mg and 1,000 mg, said in a BSE filing.

The tablets are generic versions of Bristol-Myers Squibb Company's tablets in the same strengths, it added.

The product and will be commercialised from company's Unit 2 located at Atchutapuram, Visakhapatnam in Andhra Pradesh, said.

Shares of Laurus Labs today closed at Rs 438.70 per scrip on BSE, down 0.44 per cent from its previous close.

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Wed, August 29 2018. 20:36 IST